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Diabetic heart diseaseAims: To investigate whether liraglutide improves diastolic function in type 2 diabetes.
Methods: Thirty-seven patients with type 2 diabetes who began liraglutide therapy between
June 2013 and May 2014 were enrolled in this observational, prospective study. 26 patients
received liraglutide therapy for at least 6 months. The remaining 11 patients withdrew from
liraglutide therapyduring thefirstmonth,werestartedonotherhypoglycaemic therapiesand
formed the control group. Anthropometric, metabolic and echocardiographic parameters
including pulsed wave tissue Doppler imaging were evaluated at baseline and at 6 months.
Results: In the liraglutidegroup theearlydiastolicmitral annulusvelocityon the lateral (e-lat)
and medial (e-med) sides of the mitral annulus increased from 9.2 ± 3.4 to 11.6 ± 4.7 cm/s
(p < 0.001) and from 6.9 ± 1.7 to 8.4 ± 2.6 cm/s (p < 0.003), respectively. The ratio of early-to-
late velocities on the lateral and medial sides of the mitral annulus increased from 0.7 ± 0.3
to 0.9 ± 0.4 (p < 0.001) and from 0.5 ± 0.1 to 0.6 ± 0.1 (p < 0.02), respectively. The ratio of early
diastolic mitral inflow velocity to early diastolic myocardial relaxation velocity decreased
from 10.7 ± 4.3 to 8.5 ± 2.5 (p < 0.005). No improvements in diastolic function was detected
in the control group. Glucose control improved similarly in both groups: HA1bc 1.5%
(17 mmol/mol) vs 1.3% (14 mmol/mol), p = 0.67.
Conclusions: In patients with type 2 diabetes, 6 months liraglutide treatment was associated
with a significant improvement in diastolic function.
 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Cardiovascular complications are the main cause of diabetes-
related morbidity and mortality [1]. Diabetic cardiomyopathy
(DCM) increases the risk of heart failure and death regardless
of coexisting coronary artery disease or concomitant riskfactors [2,3]. The prevalence of DCM in patients with type 2
diabetes (T2D) may be as high as 60% [4]. DCM is character-
ized by a wide range of structural abnormalities, including
ventricular dilation, myocardial fibrosis and steatosis, car-
diomyocyte apoptosis, amyloid deposition and interstitial
edema. The pathogenesis of DCM involves a multifactorialrtment of
0285994033.
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tributor [5]. The pathological role of endoplasmic reticulum
oxidative stress has recently been underlined [6,7].
Diastolicdysfunction (DD) is the leadingelementofDCM[8].
In particular, left ventricular DD (LVDD) is characterized by
impaired early diastolic filling, prolonged isovolumetric relax-
ation and increased atrial filling. It has been described as an
early sign of diabeticmyocardial disease, and precedes systolic
damage and heart failure [9,10]. Cardiac catheterization is the
gold standard for assessingDD [11]. However, cardiac catheter-
ization is invasive and cannot be performed in everyday clini-
cal practice [12]. Doppler echocardiography has emerged as
an important, noninvasive, diagnostic tool for DD [13].
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor ago-
nist, is a new therapeutic tool for T2D. It has considerable effi-
cacy in glycemic control and weight loss, good safety and a
low risk of causing hypoglycemia [14–17]. Liraglutide has also
been shown to have a beneficial effect on the cardiovascular
system in both animals and humans [18]. Furthermore, it is
known that the GLP-1 receptors are widely expressed in heart
and vessels [19].
Preclinical and clinical trials have concentrated on the
cardioprotective benefits of liraglutide by decreasing blood
pressure, promoting weight loss and improving the lipid pro-
file [20]. A randomized trial called ‘‘liraglutide effects and
action in diabetes: evaluation of cardiovascular outcome
results” (LEADER), is currently ongoing [21].
There is some evidence of positive effects of liraglutide in
animal models [22] and humans with ischemic heart disease
[23] or after reperfusion [24]. In these models, liraglutide
increased regional wall motion, cellular tolerability to ische-
mia and the ejection fraction, and reduced infarct size [25].
Studies of the effects of liraglutide on DCM are limited and
have all been performed in animals. A GLP-1 receptor agonist
(GLP-1 RA) increased myocardial glucose uptake indepen-
dently of its ability to enhance insulin secretion and
enhanced survival of cardiac cells, improving overall cardiac
function [26]. There are currently no published studies on
the effects of liraglutide on DCM in humans.
Thus, the aim of this study was to evaluate the effects of
6 months treatment with liraglutide on DCM in patients with
T2D.2. Methods
2.1. Patients
Patients with T2D who began liraglutide therapy in our Dia-
betes Unit between June 2013 and May 2014 were enrolled
in this observational, prospective study. Diagnosis of diabetes
was made according to current American Diabetes Associa-
tion criteria [27]. Diagnosis of DD was made according to
the American Society of Echocardiography (ASE) and the
European Association of Echocardiography (EAE) recommen-
dations [28]. All patients gave written informed consent for
the use of personal data. Study protocol was approved by local
ethic committee. Other inclusion criteria were age between 18
and 80 years, inadequate glycemic control before introducing
therapy with liraglutide (glycated hemoglobin [HbA1c] >7.0%or >53 mmol/mol), and no clinical history of acute coronary
syndrome, myocardial revascularization or heart failure clas-
sified as a New York Heart Association (NYHA) class III or IV.
Exclusion criteria were a diagnosis of type 1 diabetes, baseline
HbA1c > 12% (108 mmol/mol), active neoplasia, hepatic dys-
function (defined as alanine aminotransferase and aspartate
aminotransferase more than three times the upper limit of
normal values), pregnancy and severe chronic kidney disease
(defined as estimated glomerular filtration rate <30 mL/
min/1.73 m2). Patients with a psychiatric disorder or history
of alcohol or drug abuse were excluded. Before initiating
liraglutide therapy, all patients were receiving hypoglycemic
therapy, as monotherapy or in combination. Most patients
were treated with lipid-lowering and anti-hypertensive drugs
(Table 1). No modifications to lipid-lowering drugs or anti-
hypertensive therapies were allowed during the study period.
Of 37 enrolled patients, 26 completed 6 months therapy
and constituted the liraglutide group (LG).
Liraglutide was prescribed in accordance with the current
clinical guidelines.
In all of patients, liraglutide was started at a dose of
0.6 mg/day, increased to 1.2 mg/day after 1 week. In patients
with insufficient glycemic response, the dose was further
increased during the first month, up to 1.8 mg/day.
Patients who withdrew liraglutide therapy within the first
month were started on other hypoglycemic therapies that
did not include GLP-1 RA or dipeptidyl peptidase-IV inhibitors
(DPP-4i). These 11 patients were used as the control group
(CG).
2.2. Outcome measures
Anthropometric, metabolic and echocardiographic parame-
ters were evaluated at baseline and at 6 months from the
beginning of therapy. Clinical parameters, side effects, and
glycemic reports were evaluated at 2 weeks and 4 weeks after
the beginning of therapy and then as needed.
2.2.1. Anthropometric and metabolic parameters
Data were collected at baseline and 6 months after the begin-
ning of therapy for age, sex, duration of diabetes, presence of
diabetes complications, height, body weight (BW), body mass
index (BMI), waist circumference (WC), systolic blood pres-
sure (SBP), diastolic blood pressure (DBP) and history of previ-
ous anti-diabetic therapy. HbA1c was measured by a DCCT-
aligned high-performance liquid chromatography (Tosoh Cor-
poration, Tokyo, Japan); fasting blood glucose (FBG) by glucose
hexokinase method, total cholesterol, high-density lipopro-
tein cholesterol (HDL-C) and triglycerides by an enzymatic
method (ADVIA Chemistry Systems 1800, Siemens Healthcare
Diagnostics Inc., Tarrytown, NY, USA); the low-density
lipoprotein cholesterol (LDL-C) was calculated by the Friede-
wald formula.
2.2.2. Echocardiographic parameters
Transmitral PW Doppler analysis was used to evaluate peak
early (E) and late (A) ventricular filling velocities, E/A ratio,
deceleration time (DT) of early filling velocity, and isovolumic
relaxation time. PW-TDI was used to evaluate early (e0) and
late (a0) diastolic peak velocities on the lateral (lat.) and septal
Table 1 – Baseline characteristics.
Liraglutide group Control group
N (M/F) 26 (15/11) 11 (7/4)
Age (years) 61.7 ± 10* 63.5 ± 10.7
Diabetes duration (years) 11.1 ± 8.4* 13.0 ± 12.0
Hypoglycemic drugs
Metformin (%) 84.6 60.0
Sulfonylureas/glinides (%) 23.0 20.0
Acarbose (%) 3.8 0.0
Pioglitazone (%) 15.3 0.0
Dipeptidyl peptidase-IV inhibitors (%) 30.7 6.6
Insulin (%) 30.7 33.3
Other medications
Statins (%) 61.5 33.3
Angiotensin-converting-enzyme inhibitors (%) 30.7 26.6
Sartans (%) 23.1 40.0
Beta blockers (%) 34.6 26.6
Calcium channel blockers (%) 23.1 13.3
Diuretics (%) 19.2 53.3
Continuous data are presented as mean ± standard deviation.
* p: NS compared to control.
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and the ratio of early diastolic mitral inflow velocity (E) to
early diastolic myocardial relaxation velocity (a0 average).
PW Doppler analysis of pulmonary venous flow was used to
evaluate peak antegrade systolic (S) and diastolic (D) veloci-
ties, the S/D ratio, and peak velocity and duration of atrial
reversal (Ar) in late diastole.
Normal diastolic function was defined as e0 med.P 8 cm/s
and e0 lat.P 10 cm/s [29]. DD was defined as e0 med. < 8 cm/s
or e0 lat. < 10 cm/s, and was classified according to ASE/EAE
recommendations [28] as Grade I (mild) if E/A < 0.8,
DT > 200 ms and E/e0 average 6 8; Grade II (moderate) if E/A
0.8–1.9, DT 160–200 ms and E/e0 average 9–12; and Grade III
(severe) if E/AP 2, DT < 160 ms and E/e0 averageP 13 [28,29].
All echocardiograms were performed by the same cardiol-
ogist using the same ultrasound system (Philips CX 50 with
2.5–3.5 MHz probes).
2.3. Statistical analysis
Continuous data are expressed as mean ± standard deviation.
Categorical data are presented as percentage. Normality of
data was evaluated with the Kolmogorov–Smirnov test.
Within each group, a paired Student’s t test was used to com-
pare means between baseline and 6 months. At baseline an
unpaired two-tailed Student’s t test was used to compare
means between the liraglutide and control groups; at
6 months Student’s t test was used to compare changes in
metabolic parameters. Linear regression was used to quantify
the relation between the change in metabolic variables
(HbA1c, body weight) and the change in diastolic function
(e0 on the lateral side of the mitral annulus). Statistical signif-
icance was accepted at p < 0.05. Data were analyzed using
SPSS software, version 20.3. Results
Thirty-seven patients with T2D (22 men, 15 women) were
recruited. In 11 patients (7 men, 4 women), liraglutide therapy
was interrupted during the first month because of gastroin-
testinal side effects (such as nausea or vomiting) or inefficacy.
In these patients, an improvement of glucose control was
obtained using other hypoglycemic agents, such as met-
formin, sulfonylureas, glinides or insulin. These patients
formed the CG. Patient characteristics are provided in Table 1.
At baseline, there were no differences in clinical characteris-
tics or metabolic variables between the two groups (Tables 1
and 2, respectively). Twenty-six patients received liraglutide
therapy for at least 6 months. In 18 patients, the dose of
liraglutide was 1.2 mg/day throughout the study period; in
the remaining 8 patients, it was increased to a maximum of
1.8 mg/day over the first month.
3.1. Metabolic parameters
At baseline, the mean BMI of the LG was in the range classi-
fied as obese (32.8 ± 4.2 kg/m2) and glycemic control was poor
(HbA1c: 9.0 ± 1.6% [75 ± 18 mmol/mol]; fasting blood glucose:
190.8 ± 56.2 mg/dl). After 6 months of treatment with liraglu-
tide, there were significant improvements in glycemic control
(DHbA1c: 1.5% [17 mmol/mol], p = 0.0006; DFBG: 38.9 mg/
dl, p = 0.074) and anthropometric parameters (DBW: 3.7 kg,
p = 0.0005; DBMI: 1.2 kg/m2, p = 0.0009; DWC: 1.6 cm,
p = 0.019; Table 2).
At baseline, the mean BMI of the CG group was also in the
range classified as obese (35 ± 6.1 kg/m2) and glycemic control
was also poor (HbA1c: 9.0 ± 1.8% [75 ± 20 mmol/mol]; FBG:
186.2 ± 76.4 mg/dl; Table 2). After 6 months of treatment,
there was a significant improvement in HbA1c (DHbA1c:
Table 2 – Metabolic parameters.
Liraglutide group Control group
Baseline 6 months p Baseline 6 months p
HbA1c (%) 9.0 ± 1.6* 7.5 ± 1.3 0.0006 9.0 ± 1.5 7.7 ± 1.3 0.042
FPG (mg/dl) 190.8 ± 56.2* 151.9 ± 43.2 0.074 196.2 ± 76.4 157.1 ± 68.4 0.22
BW (kg) 91.0 ± 15.4* 87.3 ± 15.3 0.0005 90.9 ± 19.6 91.3 ± 18.3 0.96
WC (cm) 112.6 ± 11.9* 111.0 ± 10.4 0.019 119.3 ± 14.0 119.7 ± 13.6 0.94
BMI (kg/m2) 32.8 ± 4.2* 31.6 ± 4.1 0.0009 35.0 ± 6.1 35.2 ± 5.7 0.93
SBP (mmHg) 130.4 ± 17.5* 129.0 ± 13.8 0.75 137.5 ± 18.9 137.3 ± 19.2 0.98
DBP (mmHg) 76.9 ± 9.8* 77.1 ± 9.3 0.94 77.5 ± 16.7 81.1 ± 17.0 0.62
TC (mg/dl) 175.0 ± 30.5* 163.4 ± 32.4 0.19 203.3 ± 84.3 195.2 ± 81.6 0.82
HDL (mg/dl) 48.9 ± 12.0* 48.6 ± 10.6 0.92 47.5 ± 8.1 48.1 ± 7.5 0.85
TG (mg/dl) 173.2 ± 122.8* 134.7 ± 84.5 0.19 200.7 ± 104.2 187.4 ± 89.3 0.75
LDL (mg/dl) 92.4 ± 26.3* 88.3 ± 29.9 0.6 92.0 ± 26.3 91.3 ± 24.8 0.95
Abbreviations: HbA1c, glycated hemoglobin; FPG, fasting blood glucose; BW, body weight; WC, waist circumference; BMI, body mass index, SBP,
systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; HDL, high-density lipoproteins; TG, triglycerides; LDL, low-density
lipoproteins.
* p: NS compared to baseline in control group.
 p: NS when compared the improvement between the two groups.
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nificant changes in FBG or anthropometric parameters.
The improvement in HbA1c from baseline to 6 monthswas
similar in the two groups (p = 0.67). DFBG was similar between
the two groups (38.9 for LG, 39.1 for CG), but was significant
only for the LG; this was likely due to the different numerosity
of the two groups.Table 3 – Echocardiographic parameters.
Liraglutide group
Baseline 6 months
Transmitral PW Doppler imaging
E-wave (cm/s) 79.9 ± 17.1* 82.4 ± 14.9
DT (m/s) 181.3 ± 32.6* 184.5 ± 23.9
A-wave (cm/s) 97.0 ± 18.5 99.1 ± 18.8
E/A ratio 0.8 ± 0.2* 0.8 ± 0.2
IVRT (ms) 79.9 ± 13.3* 78 ± 12.7
PW tissue Doppler imaging
e0 lat.-wave (cm/s) 9.2 ± 3.4* 11.6 ± 4.7
a0 lat.-wave (cm/s) 13.8 ± 3.3* 14.5 ± 4.0
e0/a0 lat. ratio 0.7 ± 0.3* 0.9 ± 0.4
e0 med.-wave (cm/s) 6.9 ± 1.7* 8.4 ± 2.6
a0 med.-wave (cm/s) 12.6 ± 3.0* 13.1 ± 3.5
e0/a0 med. ratio 0.5 ± 0.1* 0.6 ± 0.1
E/e0 average ratio 10.7 ± 4.3* 8.5 ± 2.5
PW Doppler imaging of pulmonary venous flow
S-wave (cm/s) 64.0 ± 14.7* 60.9 ± 11.8
D-wave (cm/s) 46.2 ± 6.5* 47.6 ± 7.1
S/D ratio 1.4 ± 0.2* 1.2 ± 0.2
Ar-wave (cm/s) 36.8 ± 6.8* 33.6 ± 6.3
Ar-wave duration (ms) 119.7 ± 19.3* 107.1 ± 17.7
*p: NS and p = 0.0112 compared to baseline in control group. Abbreviation
of early filling velocity; A-wave, peak late ventricular filling velocity; IVRT
on the lateral side of the mitral annulus; a0 lat.-wave, late diastolic peak
diastolic peak velocity on the medial side of the mitral annulus; a0 med
annulus; S-wave, peak antegrade systolic velocity; D-wave, peak antegra
diastole; Ar-wave duration, duration of atrial reversal in late diastole.Lipid profile of both groups was typical of secondary dys-
lipidemia at baseline and was unchanged after treatment,
such as mean SBP and DBP (Table 2).
3.2. Echocardiographic parameters
The echocardiographic parameters reflecting diastolic func-
tion were similar in the two groups at baseline, except forControl group
p Baseline 6 months p
0.46 90.2 ± 24.3 113.0 ± 35.4 0.09
0.66 189.3 ± 37 163.3 ± 31.6 0.33
0.47 110.5 ± 8.4 119.7 ± 29.8 0.38
0.44 0.8 ± 0.3 1.0 ± 0.4 0.09
0.66 85.0 ± 17.6 79.5 ± 18.4 0.44
0.0006 9.2 ± 2.5 8.1 ± 2.0 0.31
0.30 16.3 ± 6.1 15.7 ± 4.3 0.85
0.0001 0.6 ± 0.2 0.5 ± 0.1 0.47
0.0031 7.3 ± 2.4 7.7 ± 2.2 0.78
0.51 12.3 ± 3.7 13.7 ± 5.5 0.46
0.0139 0.6 ± 0.1 0.6 ± 0.2 0.76
0.005 11.6 ± 4.3 15.5 ± 8.7 0.19
0.21 63.4 ± 6.5 73.5 ± 14.3 0.17
0.66 43.0 ± 6.8 56.8 ± 25.0 0.14
0.0255 1.5 ± 0.2 1.4 ± 0.3 0.42
0.0143 35.8 ± 6.3 35.5 ± 6.1 0.95
0.0097 127.3 ± 18.3 120.5 ± 19.9 0.65
s: E-wave, peak early ventricular filling velocity; DT, deceleration time
, isovolumic relaxation time; e0 lat.-wave, early diastolic peak velocity
velocity on the lateral side of the mitral annulus; e0 med.-wave, early
.-wave, late diastolic peak velocity on the medial side of the mitral
de diastolic velocity; Ar-wave, peak velocity of atrial reversal in late
R2 = 0.203 
P= 0.031
Fig. 1 – Correlation between the improvement in diastolic function and the decrease of HbA1c in LG. LG, liraglutide group. De0
lat, early diastolic peak velocities on the lateral side of the mitral annulus. HbA1c, glycated hemoglobin.
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(42%) had Grade I (mild) DD and 15 patients (58%) had Grade
II (moderate) DD. In the CG at baseline, four patients (36%)
had Grade I DD and seven patients (64%) had Grade II DD.
No patient had NYHA class II-IV.
After 6 months of liraglutide therapy, the following differ-
ences with respect to baseline were observed in the LG
(Table 3): an increase in e0 on both sides of the mitral annulus
(e0 lat. and e0 med.); an increase in the e0/a0 lat. and e0/a0 med.
ratios; a reduction in the E/e0 ratio; a reduction in the S/D ratio
on the right superior pulmonary vein; a reduction in the peak
Ar velocity on the right superior pulmonary vein; and a reduc-
tion in the Ar-wave duration on the right superior pulmonary
vein. Seventeen patients (65%) in the LG exhibited an
improvement in diastolic function, 10 of them (38%) achieved
normal diastolic function on the last control.
In the LG, there was a significant correlation between the
improvement in diastolic function (expressed as De0 lat.) and
the decrease in HbA1c (R2 = 0.203, p = 0.031; Fig. 1). There
was no correlation between the improvement in diastolic
function and the decrease in BW (R2 = 0.048, p = 0.302; Fig. 2).
By contrast, in the CG, no echocardiographic parameters
changed significantly from baseline to 6 months.
In addition, no patient in the CG exhibited normal diastolic
function, no patient exhibited an improvement in DD grade
and two patients exhibited a worsening of DD grade.
Systolic function did not change from baseline to
6 months in either group.4. Discussion
Previous studies have demonstrated that liraglutide has pos-
itive effects not only on glycemic and weight control inhumans [14], but also on left ventricular diastolic function
in animals [6,7]. In this study, we have shown for the first time
that liraglutide significantly improved diastolic function in
human patients with T2D treated for 6 months. Our results
showed a significant improvement in several diastolic func-
tion parameters measured using PW-TDI and PW Doppler of
pulmonary venous flow. These techniques are not routinely
used in clinical practice, but are more sensitive than transmi-
tral Doppler technique [30].
Although preliminary, these results are supported by the
complete lack of improvement in diastolic function in the
CG, in whom glycemic control was achieved with hypo-
glycemic drugs other than GLP-1 RA and DPP-4i. No signifi-
cant echocardiographic changes were observed in the CG,
despite a decrease in HbA1c similar to that observed in the
LG.
However, the finding in the LG that the increase in e0 lat. (a
marker of overall diastolic function) was significantly and
inversely related to the decrease in HbA1c suggests that the
metabolic changes may have been involved in the improve-
ment in cardiac function.
It is well known that a reduction in body weight and insu-
lin resistance may independently improve diastolic function
in patients with T2D [31]. In the current study, a significant
weight reduction was observed in the LG, but not in the CG,
as expected. Surprisingly, there was no significant relation
between weight loss and the improvement in diastolic func-
tion in the LG group.
The mechanism underlying these improvements can be
only speculative and both direct and indirect effects can have
a role. Many experimental data in animals have demon-
strated direct cardiovascular effects of GLP-1 receptor stimu-
lation [32,33]. Observed responses include increased cardiac
glucose uptake, modifications in free fatty acid and lipid
R2 = 0.048
P= 0.302
Fig. 2 – Correlation between the improvement in diastolic function and the decrease in body weight. De0 lat, early diastolic
peak velocities on the lateral side of the mitral annulus.
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sequent rise in vascular relaxation and thus afterload
decrease [34,35,22,26]. In patients with ischemic-reperfusion
damage and heart failure (both diabetic and non diabetic)
the effects comprehend improvement in LV ejection fraction,
regional wall motion and overall cardiac performance [36,23–
25]. The described effects have a notably rapid onset, few
weeks in the large majority of the studies.
Among the indirect effects, besides the reduction in BW
and insulin resistance, the decrease in SBP could also have
a role in the cardiac function improvement. However, at vari-
ance with other wider studies [37,38], the reduction of SBP
that we observed was not statistically significant
(1.4 mmHg) and therefore probably of little influence in our
patients. Only studies specifically designed to study this
effects such as the LEADER trial, that is currently underway,
(21) could give a definite answer.
Parameters used to evaluate diastolic function in the cur-
rent study deserve further explanation. DCM is characterized
by reduced longitudinal distensibility of the left ventricle,
with decreased filling ability and increased left atrial pres-
sure. Quantification of ventricular function in the longitudi-
nal axis is clinically relevant, as contraction and relaxation
in this direction occur mainly due to the activity of subendo-
cardial fibers [39], which exhibit the primary myocardial
effects in many cardiac diseases, including DCM. PW-TDI is
highly suited for measurement of left ventricle longitudinal
motility, because it has higher temporal resolution than other
ultrasound techniques, and thus allows measurement of
myocardial contraction and relaxation speed. Furthermore,
the PW-TDI profile of mitral annulus velocity can be consid-
ered a marker of the overall function of the left ventricle [40].
Most studies have shown the importance of sampling e0
lat. with PW-TDI for its relative independence from thepreload [41], compared to the transmitral Doppler technique
[32]. This variable is rarely affected by ischemic processes
and its measurement is easier and reproducible [42]. In this
study, we evaluated e0 peak velocities on the medial and lat-
eral sides, and found a significant increase in both e0 med.
and e0 lat. from baseline to 6 months. Moreover, e0 med.
reached the threshold of normality for healthy adults
(>8 cm/s) [28]. These findings describe an improvement in
longitudinal motility, which is reflective of a gain in global left
ventricle diastolic performance. Moreover e0 velocity, consid-
ered singularly, has been shown to be an independent prog-
nostic factor [43] and the main predictor of ventricular
remodeling, acute heart failure hospitalization and post-
infarction mortality [44].
The E/e0 ratio acts as a useful and reliable noninvasive esti-
mate of left ventricle filling pressure. A decrease in the E/e0
ratio accurately reflects the downward trend in left ventricle
filling pressure as well as the improvement in left ventricle
relaxation. An E/e0 ratio <8 is considered normal [28]. In the
current study, E/e0 decreased from 10.7 to 8.5 after 6 months
of treatment with liraglutide. The importance of this result
is stressed by the relation between E/e0 and pulmonary capil-
lary pressure [32]. An E/e0 ratio >10 identifies a mean pul-
monary capillary pressure >12 mmHg, which defines
pulmonary hypertension, a severe complication of DD [28],
with sensitivity of 78% and specificity of 95%.
PW Doppler analysis of pulmonary venous flow showed an
improvement in left ventricle compliance and resistance
against blood flow, as shown by the reductions in the S/D ratio
and Ar-wave duration. The Ar-wave reflects the flow of blood
wrongly directed to the pulmonary veins due to decreased
ventricular compliance. In this study, after 6 months of treat-
ment with liraglutide, the Ar-wave peak velocity was below
the limit considered normal (<35 cm/s) [28].
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confirm these results and better explain the overall mecha-
nisms through which liraglutide may improve diastolic
function.
The limitations of this study include the reduced size of
analyzed population, the lack of an adequate CG, the differ-
ence in size between the two groups and the consequent lack
of a statistical analysis that included a correction for the ther-
apies taken by the patients.
In addition, echocardiography is a highly operator-
dependent procedure, no single criterion has been identified
to diagnose DD and the cut-off values of the various criteria
may have slight variations in different populations.
5. Conclusions
In this preliminary, independent study, liraglutide had a ben-
eficial effect on DD in patients with T2D. This is an important
finding, because DD is a known additive risk of mortality [45].
Larger, prospective clinical trials are needed to fully evalu-
ate the long-term effectiveness of liraglutide on DD and on
real cardiovascular morbidity and mortality, to better under-
stand its exact mechanisms of action, to confirm the indepen-
dence of these effects and to determine if there is a class
effect.
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